Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
In a statement Sunday, the Atlanta-based Fearless Fund said it would comply with the order but remained confident of prevailing in the lawsuit, which was brought by conservative activist Edward Blum’s American Alliance for Equal Rights.
The Week's Top Stories is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.